BCR and neoplasm: The substantial probability of missing the tumor BCR clone in the blood samples, and the scarcity of tumor samples for extracting tumor BCR sequences when patients were presented for HDT-ASCR, made the holistic approach of SDI measurement a more tractable strategy for determining the existence of malignant B cells.